drugset / Trial / NCT02195375

Flutiform® Compared With Seretide® in the Treatment of COPD

NCT02195375

Phase 2/3 Completed 923 enrolled Mundipharma Research Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate whether flutiform® is effective and safe in the treatment of chronic obstructive pulmonary disease (COPD).

Timeline

Start
2014-09
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Other / unclassified 250 ug
Subject Fluticasone Other / unclassified 500 ug
Subject Formoterol Other / unclassified 10 ug
Subject Formoterol Other / unclassified 20 ug
Comparator Salmeterol Other / unclassified 50 ug